RAPT director granted 4,956 RSUs in Form 4

RAPT Therapeutics director Linda Kozick received an annual equity grant in the form of restricted stock units.

Accepted by SEC EDGAR 02/02/2026 - 05:45 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

RAPT Therapeutics director Linda Kozick received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a stated price of $0 per unit under the company’s non-employee director compensation policy.

The RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting. Following this grant, Kozick beneficially owns 4,956 shares directly through these RSUs.

Insider Trade Summary

Grant/Award: 4,956 shares

Grant/Award 1 txn

Insider Kozick Linda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,956	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,956 shares (Direct)

Holdings Before and After: Common Stock, 0 to 4,956 shares (Direct)

Footnotes (1)

1. F1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RAPT Therapeutics (RAPT) disclose about Linda Kozick’s equity grant?

RAPT Therapeutics disclosed that director Linda Kozick received 4,956 restricted stock units on January 30, 2026. These RSUs were granted under the non-employee director compensation policy and will settle into common shares as they vest over time.

How many RAPT Therapeutics shares did Linda Kozick acquire in this Form 4?

Linda Kozick acquired 4,956 restricted stock units linked to RAPT Therapeutics common stock. Each unit represents the right to receive one share upon vesting, so she beneficially owns 4,956 shares following this reported transaction.

What are the vesting terms of Linda Kozick’s RSUs at RAPT Therapeutics?

The RSUs granted to Linda Kozick fully vest on the first anniversary of the January 30, 2026 grant date. Once vested, each restricted stock unit converts into one share of RAPT Therapeutics common stock, increasing her actual share ownership.

Did Linda Kozick pay anything for her RAPT Therapeutics RSU grant?

The Form 4 shows the 4,956 restricted stock units were granted at a price of $0 per unit. This indicates they were issued as part of her non-employee director compensation rather than purchased in an open-market or cash transaction.

Is Linda Kozick a director or officer of RAPT Therapeutics in this filing?

In this filing, Linda Kozick is identified as a director of RAPT Therapeutics and not as an officer. The grant arises under the company’s Amended & Restated Non-Employee Director Compensation Policy currently governing director equity awards.

How is Linda Kozick’s ownership in RAPT Therapeutics held after this RSU grant?

After the January 30, 2026 grant, Linda Kozick beneficially owns 4,956 derivative-linked shares through RSUs, reported as directly owned. Each RSU corresponds to one share of RAPT Therapeutics common stock upon future vesting and settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kozick Linda

(Last) (First) (Middle)

C/O RAPT THERAPEUTICS, INC.

561 ECCLES AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/30/2026		A		4,956	A	$0	4,956	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the annual grant of restricted stock units ("RSUs") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting.

	/s/ Rodney Young, Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.